Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate argenx SE - ADR before investing.

In this article, we go over a few key elements for understanding argenx SE - ADR’s stock price such as:

• argenx SE - ADR’s current stock price and volume
• Why argenx SE - ADR’s stock price changed recently
• Upgrades and downgrades for ARGX from analysts
• ARGX’s stock price momentum as measured by its relative strength

About argenx SE - ADR (ARGX)

Before we jump into argenx SE - ADR’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Want to learn more about argenx SE - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about argenx SE - ADR.

What Caused argenx SE - ADR Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of October 31, 2023, there were 2 analysts who downgraded argenx SE - ADR’s stock and 4 analysts who upgraded over the last month.

Additionally, you'll want to evaluate argenx SE - ADR’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on argenx SE - ADR’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

argenx SE - ADR’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about argenx SE - ADR (ARGX) by visiting AAII Stock Evaluator.

Relative Price Strength of argenx SE - ADR

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of October 31, 2023, argenx SE - ADR has a weighted four-quarter relative price strength of 2.94%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how argenx SE - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

argenx SE - ADR Stock Price: Bottom Line

As of November 1, 2023, argenx SE - ADR’s stock price is $494.78, which is up 5.37% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like argenx SE - ADR stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.